NO2498610T3 - - Google Patents

Info

Publication number
NO2498610T3
NO2498610T3 NO10830880A NO10830880A NO2498610T3 NO 2498610 T3 NO2498610 T3 NO 2498610T3 NO 10830880 A NO10830880 A NO 10830880A NO 10830880 A NO10830880 A NO 10830880A NO 2498610 T3 NO2498610 T3 NO 2498610T3
Authority
NO
Norway
Application number
NO10830880A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2498610(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2498610T3 publication Critical patent/NO2498610T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/781,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Oncology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO10830880A 2009-11-13 2010-11-15 NO2498610T3 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (1)

Publication Number Publication Date
NO2498610T3 true NO2498610T3 (no) 2018-08-11

Family

ID=43992106

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10830880A NO2498610T3 (no) 2009-11-13 2010-11-15
NO2020039C NO2020039I1 (no) 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2020039C NO2020039I1 (no) 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Country Status (30)

Country Link
US (4) US8362048B2 (no)
EP (3) EP2498610B2 (no)
JP (3) JP5650233B2 (no)
KR (2) KR101721716B1 (no)
CN (2) CN105061350B (no)
AU (1) AU2010319983B2 (no)
BR (2) BR122018077504B8 (no)
CA (2) CA2986521C (no)
CY (3) CY1120338T1 (no)
DK (2) DK2498610T3 (no)
EA (2) EA035768B1 (no)
ES (2) ES2673160T3 (no)
FR (1) FR20C1059I2 (no)
HK (2) HK1213874A1 (no)
HR (2) HRP20180874T1 (no)
HU (3) HUE054000T2 (no)
IL (2) IL219691B (no)
LT (3) LT3406142T (no)
MX (1) MX2012005560A (no)
MY (2) MY189750A (no)
NO (2) NO2498610T3 (no)
NZ (1) NZ599915A (no)
PH (1) PH12015502708A1 (no)
PL (2) PL2498610T3 (no)
PT (2) PT2498610T (no)
RS (2) RS61829B1 (no)
SG (1) SG10201407357PA (no)
SI (2) SI2498610T1 (no)
TR (1) TR201807912T4 (no)
WO (1) WO2011060392A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5650233B2 (ja) 2009-11-13 2015-01-07 レセプトス インコーポレイテッドReceptos, Inc. 選択的スフィンゴシン−1−リン酸受容体変調因子および不斉合成方法
PL2498611T3 (pl) * 2009-11-13 2018-07-31 Celgene International Ii Sàrl Modulatory receptora sfingozyno-1-fosforanu i sposoby chiralnej syntezy
JP6129159B2 (ja) 2011-05-13 2017-05-17 レセプトス エルエルシー 選択的複素環式スフィンゴシン1−リン酸受容体モジュレーター
HUE033583T2 (hu) * 2012-06-21 2017-12-28 Eisai R&D Man Co Ltd Új indánszulfamid származékok
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
US20170165236A1 (en) * 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CA2981743A1 (en) 2015-04-06 2016-10-13 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
WO2017215617A1 (zh) 2016-06-14 2017-12-21 苏州科睿思制药有限公司 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
BR112019001153A2 (pt) * 2016-07-22 2019-04-30 Shijiazhuang Sagacity New Drug Development Co., Ltd. agonista s1p1 e aplicação do mesmo
WO2018033149A1 (zh) * 2016-08-19 2018-02-22 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
US10882830B2 (en) 2016-09-14 2021-01-05 Receptos Llc Crystal form of ozanimod hydrochloride and processes for preparation therefor
US11117875B2 (en) 2016-09-14 2021-09-14 Hangzhou Solipharma Co., Ltd. Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
KR102408814B1 (ko) * 2016-09-29 2022-06-14 리셉토스 엘엘씨 루푸스를 치료하기 위한 화합물 및 방법
CN110325517B (zh) * 2017-02-28 2021-03-02 南京明德新药研发有限公司 螺环类化合物及其应用
US20200031784A1 (en) * 2017-04-07 2020-01-30 Solipharma Llc Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
WO2018208855A1 (en) 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
PT3630738T (pt) * 2017-05-22 2023-10-24 Egyt Gyogyszervegyeszeti Gyar Processo para a produção de ozanimod
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
US11117876B2 (en) 2017-08-31 2021-09-14 Receptos Llc Crystalline form of ozanimod hydrochloride, and processes for preparation thereof
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
CN111683946B (zh) * 2018-01-18 2022-04-05 南京明德新药研发有限公司 一种三并环化合物的晶型、盐型及其制备方法
RU2020128731A (ru) 2018-03-20 2022-04-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Средство для лечения эпилепсии
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
US20210340115A1 (en) 2018-09-12 2021-11-04 Pharmazell Gmbh A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-l-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
ES2962211T3 (es) 2018-12-07 2024-03-18 Synthon Bv Proceso mejorado para preparar ozanimod
WO2020205478A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
CN113939507A (zh) * 2019-03-29 2022-01-14 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
JP2022528001A (ja) * 2019-03-29 2022-06-07 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン1リン酸受容体調節因子
KR20220007065A (ko) * 2019-04-26 2022-01-18 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절인자
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
US20220259163A1 (en) 2019-07-16 2022-08-18 Synthon B.V. Improved process for preparing ozanimod
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
KR20220124209A (ko) * 2020-01-06 2022-09-13 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 이상의 치료 방법
EP4116295A4 (en) * 2020-03-04 2023-08-02 Helioeast Pharmaceutical Co., Ltd. TRICYCLIC COMPOUNDS AND THEIR USE
JP7307282B2 (ja) 2020-03-04 2023-07-11 ヒーリオイースト ファーマシューティカル カンパニー リミテッド ベンゾ2-アザスピロ[4.4]ノナン系化合物及びその使用
EP4121025A4 (en) * 2020-03-17 2024-03-27 Enzo Biochem Inc COMPOUNDS MODULATING THE SPHINGOSINE PATHWAY FOR THE TREATMENT OF CORONAVIRUS INFECTION
US20230183194A1 (en) 2020-04-02 2023-06-15 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
EP4321507A1 (en) * 2021-04-09 2024-02-14 Helioeast Pharmaceutical Co., Ltd. Oxadiazole-substituted spirocyclic compound and application thereof
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
JPH0825973B2 (ja) 1991-04-12 1996-03-13 シェリング・コーポレーション アシル補酵素a:コレステロールアシルトランスフェラーゼの阻害剤としての二環式アミド
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DK1057827T3 (da) * 1998-01-23 2004-01-26 Sankyo Co Spiropiperidinderivater
AR035585A1 (es) 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
CA2509218C (en) * 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
SI3889142T1 (sl) 2003-04-11 2022-10-28 Ptc Therapeutics, Inc. Spojine 1,2,4-oksadiazol benzojske kisline in njihova uporaba za zatiranje nesmiselne ter zdravljenje bolezni
CA2539438A1 (en) * 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006245349A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
WO2007019116A1 (en) 2005-08-03 2007-02-15 Novartis Ag Use of hdac inhibitors for the treatment of myeloma
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
CA2634488C (en) 2005-12-21 2016-10-04 Joseph Gabriele Catecholamine regulated protein
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク H3受容体のテトラリン拮抗薬
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP2069318B1 (en) * 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
CA2669104A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
US7834039B2 (en) 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008143729A2 (en) 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
EP3782991A1 (en) * 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
CN102066752B (zh) * 2008-06-13 2014-02-19 (学)斗源学院 具有回转阀的往复式压缩机
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
JP5650233B2 (ja) 2009-11-13 2015-01-07 レセプトス インコーポレイテッドReceptos, Inc. 選択的スフィンゴシン−1−リン酸受容体変調因子および不斉合成方法
PL2498611T3 (pl) * 2009-11-13 2018-07-31 Celgene International Ii Sàrl Modulatory receptora sfingozyno-1-fosforanu i sposoby chiralnej syntezy
MX2012005559A (es) 2009-11-13 2012-08-23 Receptos Inc Moduladores heterociclicos selectivos del receptor de esfingosina 1 fosfato.
JP6129159B2 (ja) 2011-05-13 2017-05-17 レセプトス エルエルシー 選択的複素環式スフィンゴシン1−リン酸受容体モジュレーター
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.

Also Published As

Publication number Publication date
CY1124121T1 (el) 2022-05-27
US9388147B2 (en) 2016-07-12
ES2673160T3 (es) 2018-06-20
AU2010319983A1 (en) 2012-05-31
HUE037535T2 (hu) 2018-09-28
JP2014122208A (ja) 2014-07-03
IL219691A0 (en) 2012-07-31
RS61829B1 (sr) 2021-06-30
IL267956B (en) 2021-01-31
PH12015502708B1 (en) 2016-10-17
EP2498610A4 (en) 2013-05-22
BR112012011427A2 (pt) 2015-10-06
KR20160149317A (ko) 2016-12-27
NO2020039I1 (no) 2020-11-18
KR101752124B1 (ko) 2017-06-28
US10239846B2 (en) 2019-03-26
CN102762100A (zh) 2012-10-31
SI3406142T1 (sl) 2021-08-31
MY189750A (en) 2022-03-02
EP3868377A1 (en) 2021-08-25
US20150299149A1 (en) 2015-10-22
BR112012011427B1 (pt) 2021-04-20
TR201807912T4 (tr) 2018-06-21
ES2858337T3 (es) 2021-09-30
US20110172202A1 (en) 2011-07-14
HK1213874A1 (zh) 2016-07-15
CN105061350B (zh) 2018-05-29
SI2498610T1 (en) 2018-07-31
EA035768B1 (ru) 2020-08-07
JP5650233B2 (ja) 2015-01-07
US8362048B2 (en) 2013-01-29
FR20C1059I1 (no) 2020-12-25
HRP20210446T1 (hr) 2021-05-14
EA024801B1 (ru) 2016-10-31
FR20C1059I2 (fr) 2021-12-10
BR122018077504B8 (pt) 2021-05-25
AU2010319983A2 (en) 2013-09-12
BR122018077504B1 (pt) 2021-05-11
SG10201407357PA (en) 2014-12-30
EP3406142B1 (en) 2020-12-23
PT3406142T (pt) 2021-03-26
PL3406142T3 (pl) 2021-08-30
LT3406142T (lt) 2021-06-10
DK3406142T3 (da) 2021-03-22
EA201690391A1 (ru) 2016-08-31
CY1120338T1 (el) 2019-07-10
MY161854A (en) 2017-05-15
BR112012011427B8 (pt) 2021-05-25
EP2498610B1 (en) 2018-03-14
KR101721716B1 (ko) 2017-04-10
KR20120102704A (ko) 2012-09-18
CN105061350A (zh) 2015-11-18
CA2986521C (en) 2020-06-30
IL267956A (en) 2019-09-26
CY2020035I1 (el) 2021-03-12
EA201290323A1 (ru) 2013-05-30
CY2020035I2 (el) 2021-03-12
IL219691B (en) 2019-07-31
RS57253B1 (sr) 2018-08-31
US20130231326A1 (en) 2013-09-05
NZ599915A (en) 2014-07-25
EP2498610A1 (en) 2012-09-19
HK1175948A1 (en) 2013-07-19
LTC2498610I2 (lt) 2022-06-10
EP2498610B2 (en) 2024-06-19
PL2498610T3 (pl) 2018-08-31
AU2010319983B2 (en) 2015-03-12
PH12015502708A1 (en) 2016-10-17
CA2780772A1 (en) 2011-05-19
CA2986521A1 (en) 2011-05-19
WO2011060392A1 (en) 2011-05-19
US20170320839A1 (en) 2017-11-09
LTPA2020533I1 (lt) 2020-12-10
HUE054000T2 (hu) 2021-08-30
JP5982705B2 (ja) 2016-08-31
LT2498610T (lt) 2018-06-11
EP3406142B8 (en) 2021-03-03
JP2013510885A (ja) 2013-03-28
PT2498610T (pt) 2018-06-19
MX2012005560A (es) 2012-10-05
EP3406142A1 (en) 2018-11-28
JP2015038145A (ja) 2015-02-26
DK2498610T3 (en) 2018-06-14
CA2780772C (en) 2018-01-16
CN102762100B (zh) 2015-07-01
HRP20180874T1 (hr) 2018-07-13
HUS2000045I1 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
FR20C1059I1 (no)
BR112012008267A2 (no)
BR112012008195A2 (no)
BRPI0924307A2 (no)
BR122021004633A2 (no)
BR112012003080A2 (no)
BR122017024704A2 (no)
BR112012000665A2 (no)
BR112012009797A2 (no)
BR112012009446A2 (no)
BR112012009703A2 (no)
BR112012010357A2 (no)
BR112012007656A2 (no)
BR122019005883A2 (no)
BR112012002627A2 (no)
BR112012001263A2 (no)
BR112012000159A2 (no)
BRPI0924534A2 (no)
BR112012007654A2 (no)
BR112012007672A2 (no)
BR112012000255A2 (no)
BR112012000156A2 (no)
BRPI0924617A2 (no)
BR122017013721A2 (no)
BR112012009404A2 (no)